Guselkumab, sold under the brand name Tremfya, is a monoclonal antibody against interleukin-23 used for the treatment of plaque psoriasis. Guselkumab...
14 KB (1,037 words) - 04:45, 6 July 2024
use of hydroxyurea in chronic palmoplantar pustulosis. Treatment with guselkumab, an anti–interleukin 23 monoclonal antibody has shown a decrease in the...
4 KB (333 words) - 18:29, 9 December 2023
www.medicalnewstoday.com. 2021-08-15. Retrieved 2021-10-01. "Study: Guselkumab More Effective Than Secukinumab in Certain Subpopulations". Dermatology...
25 KB (1,860 words) - 23:03, 7 June 2024
the target of the FDA-approved ustekinumab. In 2017 the US FDA approved guselkumab for plaque psoriasis. There have been few studies of the efficacy of anti-TNF...
115 KB (12,963 words) - 23:33, 14 July 2024
IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27...
22 KB (1,789 words) - 04:29, 16 July 2024
against this cytokine, is used to treat certain autoimmune conditions. Guselkumab is another monoclonal antibody against IL-23. Blocking IL-23 can slow...
20 KB (2,192 words) - 23:02, 27 November 2023
the first of MorphoSys’ platform drugs received US marketing approval. Guselkumab (brand name Tremfya), which was developed and is being commercialized...
17 KB (1,409 words) - 10:53, 21 June 2024
Brodalumab L04AC13 Ixekizumab L04AC14 Sarilumab L04AC15 Sirukumab L04AC16 Guselkumab L04AC17 Tildrakizumab L04AC18 Risankizumab L04AC19 Satralizumab L04AC20...
3 KB (367 words) - 15:37, 25 January 2024
Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab Humanized Anrukinzumab...
38 KB (4,304 words) - 20:57, 1 December 2023
IL-23 Agonists: Interleukin 23 (SGRF) Antibodies: Brazikumab Briakinumab Guselkumab Risankizumab Tildrakizumab Ustekinumab IL-27 Agonists: Interleukin 27...
43 KB (3,662 words) - 19:35, 12 July 2024